Early OCT Angiography Changes of Macular Neovascularization in Patients with Exudative AMD Treated with Brolucizumab in a Real-World Setting

Figure 3

Treatment response after brolucizumab therapy assessed by optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA) at baseline, 12 weeks after the upload (week 20), and at the end of the follow-up period. A 91-year-old woman with type 1 macular neovascularization (MNV) on OCTA with intraretinal fluid (IRF) and a fibrovascular pigment epithelium detachment on OCT with a complete regression of IRF and a reduction in PED height 12 weeks after three monthly loading doses of brolucizumab (week 20). The macula stayed dry and PED height decreased further after 3 more injections every 12 weeks at the end of the follow-up period (15 months). The MNV area assessed by OCTA decreased at week 20 and decreased further at 15 months.